Vanda Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Vanda Pharmaceuticals
Starting stock price: $24.83
Ending stock price: $6.88
Percent Change: -72.29%

Details: Vanda Pharmaceuticals has three in-development candidates, all focused on nervous system disorders. In September 2007, it filed a NDA for its antipsychotic med iloperidone. In a clinical trial the drug showed efficacy against schizophrenia symptoms but some developed an irregular heartbeat; the company plans to couple genetic testing with its drug to identify those likely to experience the heart problem. Its two other possibles are targeted at sleep and mood problems. One is in Phase III and the other recently wrapped up a Phase II study.

More News:
Vanda gains on late-stage sleep trial data. Report

Vanda Pharmaceuticals - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.